A believer Lipodystrophy-associated metabolic syndrome in patients with HIV
About ETGA:
“The European AIDS Treatment Group (EATG) is a patient-led NGO that advocates for the rights and interests of people living with or affected by HIV/ AIDS and related co-infections within the WHO Europe region. Founded in 1992, the EATG is a network of more than 150 members from 45 countries in Europe. Our members are PLHIV and representatives of different communities affected by HIV/AIDS and co-infections. EATG represents the diversity of more than 2.3 million people living with HIV in Europe as well as those affected by HIV/AIDS and co-infections.”
I don’t believe there is a need to post all current ongoing trials evaluating Tesamorelin’s additional direct therapeutic benefits for various conditions as it has been posted many times.
To sell a product one needs quality, awareness and sale experience.
As for Tesamorelin it seems many additional therapeutic benefits including effects on indirect co morbidity caused by lipodystrophy(not a cosmetic condition) is getting attention so the quality and awareness(among medical community and PLWH)parts are keeping building up. As for sale experience I can tell you apart from now in house sale force( much easier to track performance and making adjustments/improvements) they have re shuffled the team with many new recruits in the last few months as per their LinkedIn people section. So all the ingredients one would anticipate to a decent sale growth are in place that’s why I believe Tesamorelin should have much better numbers going forward and it seems the company also believes that committing to the latest loan and it’s sale related milestones.